Updated:
REPAIR Impact Fund
The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest in companies involved in discovering and early-stage...
REPAIR Impact Fund
The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest in companies involved in discovering and early-stage development of therapies targeting resistant microorganisms.
General information
Firm type
Private Equity
Year founded
2018
AUM
Undisclosed
Location
Region
Europe
Country
Denmark
City
Hellerup
Corporate office
Hellerup, Denmark
Sector focus
Frequently asked questions
Who launched the REPAIR Impact Fund and why?
Novo Holdings, the holding company of the Novo Nordisk Foundation, established the fund. Its mission is to replenish the anti-infective drug pipeline by investing in early-stage therapies that target resistant microorganisms, a space many investors have left.
What investment stages does the REPAIR Impact Fund target?
The fund invests at the very beginning of drug development, covering seed-stage, start-up, and spin-off companies. It does not focus on later-stage clinical trials or approved products.
How is the REPAIR Impact Fund related to Novo Nordisk?
The fund is not part of the pharmaceutical company Novo Nordisk A/S. It sits under Novo Holdings, which manages the assets of the Novo Nordisk Foundation, the controlling shareholder of Novo Nordisk A/S and Novozymes A/S.
Does the fund make direct equity investments or use other structures?
The fund invests directly in companies. Publicly available information confirms an equity investment model for its portfolio, though the fund does not disclose specific deal terms or co-investment partners.
Which sectors does the REPAIR Impact Fund work in?
The fund is exclusively focused on digital health, specifically the discovery and early development of therapies to combat antimicrobial resistance. It does not invest in other healthcare areas or outside life sciences.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: